Pfizer Inc. has big ambitions for tafamidis as it launches the new drug in a rare cardiovascular indication, but the commercial ramp up is expected to be slow and success will depend on the company's ability to build disease awareness and diagnosis.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?